Skip to main content

US ClosedU.S. Closed

NKTX: Nkarta, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Nkarta, Inc. , a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment.

52W Range

52ndpctl

Volume

0.56×avg

Market Cap

197.47MUSD

P/E Ratio

-1.8TTM

Div Yield

-ann

Loading chart data...

Current StateState loading

Nkarta, Inc.

NKTXNASDAQ·USD·Closed

Nkarta, Inc.

NKTXNASDAQ·USD·Closed

$2.76

+0.36%

$2.76

+$0.01 (0.36%)

52W Range

52ndpctl

Volume

0.56×avg

Mkt Cap

197.47MUSD

P/E

-1.8TTM

Div Yield

–ann